Researchers from Curacle Co. Ltd. and Yonsei University have published preclinical data for the endothelial dysfunction blocker CU06-1004 from studies assessing it in models of retinal vascular disease.
Exegenesis Bio (Hangzhou Exegenesis Biotechnology Co. Ltd.) has received FDA clearance of its IND application for EXG-102-031, a recombinant adeno-associated virus (rAAV)-based gene therapy that is being studied for the treatment of neovascular age-related macular degeneration (AMD).
Traumatic optic neuropathy (TON) is a serious complication combining craniocerebral, orbital and facial injuries. While there is currently no reliable animal model of this condition, it has been previously demonstrated that TON can cause the loss of retinal ganglion cells (RGC). In the current study, researchers from Shanghai Jiaotong University developed a novel mouse model of distal TON, with the aim of assessing the cascade reactions of RGCs in this disease.
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in persons over the age of 50. While poorly understood, AMD pathogenesis begins with structural disorganization of the outer-blood-retina-barrier (oBRB), containing retinal pigment epithelium (RPE) and associated Bruch’s membrane.
Neurophth Therapeutics Inc. has received FDA clearance of its IND application for the in vivo gene replacement therapy NFS-02, a novel recombinant adeno-associated viral serotype 2 vector (rAAV2) containing a codon-optimized NADH-dehydrogenase subunit 1 (ND1) gene, for the treatment of Leber hereditary optic neuropathy (LHON) associated with ND1 mutation.